| Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab | Gynecologic Oncology Reports |  | | 2021 | 268 | 154 |
|
| Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss | Cancer Biology and Therapy | | | 2020 | 359 | 221 |
|
| Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry | Journal of Chromatography. B |  | | 2018 | 284 | 0 |
|
